Cargando…
Continuation of Liraglutide during Fasting is not Associated with Hypoglycaemia
Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, is increasingly used in obese patients with type 2 diabetes mellitus (T2DM) in doses of up to 3.0 mg/day because of its attractive pharmacological profile. It is currently not known how to proceed with this medication during fasting for surgery....
Autores principales: | Koot, Rosalie, van Borren, Marcel, de Boer, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SMC Media Srl
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346799/ https://www.ncbi.nlm.nih.gov/pubmed/30755910 http://dx.doi.org/10.12890/2017_000712 |
Ejemplares similares
-
Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017) -
Continuous glucose monitoring for children with hypoglycaemia: Evidence in 2023
por: Worth, Chris, et al.
Publicado: (2023) -
Hypoglycæmia
Publicado: (1934) -
PET imaging during hypoglycaemia to study adipose tissue metabolism
por: Boss, Marti, et al.
Publicado: (2019) -
Should continuous glucose monitoring be used to manage neonates at risk of hypoglycaemia?
por: Kalogeropoulou, Maria-Sofia, et al.
Publicado: (2023)